Am I a Candidate for Spravato? Understanding Eligibility for Esketamine Treatment at Innovative MindCare in Chicago and Downers Grove

Depression affects millions of adults across the United States, and for a significant portion of those individuals, standard antidepressant medications may not deliver adequate relief. If you have been navigating the exhausting cycle of trying one medication after another without meaningful improvement, you may be wondering whether newer treatment options could help. Spravato treatment in Chicago has become an increasingly sought-after option for adults living with treatment-resistant depression, and understanding whether you qualify is an important first step. At Innovative MindCare, serving patients in both Chicago and Downers Grove, Illinois, the clinical team works closely with individuals to evaluate eligibility and determine if Spravato (esketamine nasal spray) may be an appropriate addition to their treatment plan.

What Is Spravato and How Does It Differ from Traditional Antidepressants?

Spravato is the brand name for esketamine, a nasal spray that was approved by the U.S. Food and Drug Administration (FDA) for specific depressive conditions. Unlike traditional oral antidepressants, which primarily target serotonin, norepinephrine, or dopamine pathways and can take weeks to produce noticeable effects, Spravato works on the brain’s glutamate system. Glutamate is the most abundant excitatory neurotransmitter in the brain, and by modulating its activity, Spravato may help restore neural connections that have been disrupted by chronic depression.

It is important to note that Spravato is not the same as general ketamine therapy. While esketamine is chemically related to ketamine, Spravato is a distinct, FDA-approved pharmaceutical product with its own regulatory framework, clinical protocols, and approved indications. At Innovative MindCare, Spravato is administered as part of a structured, medically supervised program in compliance with the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, which ensures patient safety throughout every session.

FDA-Approved Indications: Who Is Spravato Designed to Help?

Spravato has received FDA approval for two specific clinical indications in adults. Understanding these approved uses is essential for determining whether you may be a candidate.

Treatment-Resistant Depression (TRD) in Adults

The primary indication for Spravato is treatment-resistant depression, which is generally defined as depression that has not responded adequately to at least two different oral antidepressant medications, each taken at an appropriate dose and for an adequate duration. Research suggests that approximately 30% of individuals with major depressive disorder may meet the criteria for treatment-resistant depression, making this a significant clinical challenge. For these individuals, Spravato used in conjunction with an oral antidepressant may help reduce depressive symptoms where other approaches have not.

Depressive Symptoms in Adults with MDD and Suicidal Ideation

Spravato is also approved for the treatment of depressive symptoms in adults who have been diagnosed with major depressive disorder (MDD) and who are experiencing acute suicidal thoughts or actions. This indication addresses a critical gap in mental health care, as traditional antidepressants can take several weeks to take effect, a timeline that may not be sufficient for individuals in acute crisis. Spravato, used alongside an oral antidepressant, has been shown to produce more rapid improvements in depressive symptoms in some patients.

Key Eligibility Criteria for Spravato Treatment in Chicago

If you are considering Spravato treatment in Chicago or the surrounding areas, there are several clinical factors that the team at Innovative MindCare will evaluate to determine your candidacy. While every patient’s situation is unique, the following criteria generally apply.

You Must Be an Adult (18 Years or Older)

Spravato is approved exclusively for use in adults. It has not been approved for pediatric or adolescent populations. During your initial consultation at Innovative MindCare, your provider will confirm that you meet this basic age requirement before proceeding with further evaluation.

You Have a Confirmed Diagnosis of Treatment-Resistant Depression or MDD with Suicidal Ideation

A thorough clinical evaluation is the foundation of determining Spravato eligibility. Your provider will review your psychiatric history, including the specific antidepressant medications you have tried, the dosages used, the length of each trial, and the outcomes. For a TRD diagnosis, you will generally need to demonstrate that at least two prior antidepressant treatments have been ineffective. Alternatively, if you carry a diagnosis of MDD and are currently experiencing suicidal thoughts or actions, this may also support your candidacy.

You Are Currently Taking or Willing to Take an Oral Antidepressant

Spravato is not intended to be used as a standalone treatment. The FDA approval specifies that it should be used in conjunction with an oral antidepressant. Your clinician at Innovative MindCare will work with you to ensure that you are on an appropriate concurrent medication regimen as part of your overall treatment plan.

You Can Commit to the Required Monitoring Protocol

Because Spravato must be administered under direct medical supervision in a certified healthcare setting, patients need to be able to commit to in-office treatment sessions. After each administration, patients are monitored for a minimum of two hours to assess for potential side effects such as sedation, dissociation, changes in blood pressure, or dizziness. You will also need to arrange transportation home after each session, as driving is not permitted on the day of treatment. At Innovative MindCare, the clinical team ensures a safe, comfortable environment for this monitoring period at both the Chicago and Downers Grove locations.

Your Medical History Supports Safe Administration

As with any medical treatment, certain health conditions may affect your eligibility. During the evaluation process, your provider will review your complete medical history, including cardiovascular health, history of substance use, and any other relevant factors. Conditions such as uncontrolled hypertension, certain vascular conditions, or a history of aneurysmal disease may require additional consideration. Your clinician will discuss any potential concerns with you in detail.

Who May Not Be a Candidate for Spravato?

While Spravato has been a meaningful addition to the treatment landscape for depression, it is not appropriate for every individual. The following factors may affect eligibility:

• Individuals under 18 years of age – Spravato is not approved for children or adolescents.
• Patients with known hypersensitivity – An allergy to esketamine, ketamine, or any of the inactive ingredients in the nasal spray formulation would be a contraindication.
• Certain cardiovascular conditions – Because Spravato can temporarily increase blood pressure, individuals with conditions such as aneurysmal vascular disease, arteriovenous malformation, or a history of intracerebral hemorrhage may not be appropriate candidates.
• Individuals seeking treatment for conditions outside the FDA-approved indications – Spravato is approved specifically for treatment-resistant depression and depressive symptoms in MDD with suicidal ideation. It is not indicated for other conditions.
• Patients unable to comply with the REMS monitoring requirements – The supervised administration and post-treatment monitoring are not optional components; they are integral to safe treatment.

If any of these factors apply to you, the clinical team at Innovative MindCare can discuss alternative approaches that may be better suited to your needs.

What to Expect During Your Eligibility Assessment at Innovative MindCare

The path to Spravato treatment in Chicago begins with a comprehensive clinical consultation. At Innovative MindCare, this process is designed to be thorough yet accessible, so patients feel informed and supported from the very first appointment.

During your initial visit, your provider will:

1. Review your psychiatric and medical history – This includes prior diagnoses, previous medication trials, therapy history, and any co-occurring medical conditions.
2. Assess your current symptoms – Standardized depression screening tools may be used to evaluate the severity of your symptoms and establish a baseline for tracking progress.
3. Discuss your treatment goals – Understanding what you hope to achieve helps your clinician develop a personalized treatment plan that aligns with your needs.
4. Explain the treatment process in detail – You will receive clear information about how Spravato is administered, the typical treatment schedule (which often begins with twice-weekly sessions during an induction phase, followed by weekly or biweekly maintenance sessions), potential side effects, and what to expect during each visit.
5. Determine your eligibility – Based on the information gathered, your provider will make a clinical determination about whether Spravato is an appropriate option for you.

This evaluation process ensures that every patient who begins Spravato treatment at Innovative MindCare does so with a clear understanding of the therapy, realistic expectations, and a clinical rationale supporting their participation.

Insurance Coverage for Spravato at Innovative MindCare

One of the advantages of Spravato compared to some other advanced treatment options is that it is typically covered by insurance. Innovative MindCare accepts several major insurance providers for Spravato treatment, including Aetna, Cigna, Blue Cross Blue Shield, UnitedHealthcare, Medicare, and Medicaid. This broader accessibility through insurance coverage has made Spravato treatment in Chicago a viable option for many patients who might otherwise face financial barriers to advanced depression care. If you have questions about your specific coverage, the team at Innovative MindCare can help guide you.

Taking the Next Step Toward Eligibility Evaluation

Living with treatment-resistant depression or major depressive disorder with suicidal ideation can feel isolating and discouraging, especially after multiple treatment attempts have not provided the relief you need. Spravato represents an evidence-based option that has helped many patients experience meaningful improvement in their depressive symptoms when other treatments have fallen short. However, determining whether it is the right fit for your unique clinical situation requires a personalized evaluation by a qualified provider.

If you are exploring Spravato treatment in Chicago or Downers Grove and want to understand whether you may be a candidate, Innovative MindCare is here to help. The experienced clinical team provides thorough eligibility assessments in a supportive, medically supervised environment that meets all REMS certification requirements. Contact Innovative MindCare today to schedule a consultation and take the first step toward learning whether Spravato may be an appropriate part of your path forward.